Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing

 
• By Brenda Sandburg
  
Neuroblastoma
FDA advisory committee favors further research on potential surrogate endpoint for high-risk neuroblastoma • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers